Effect of antiepileptic medication on bone mineral measures

Neurology

Volumn 65, Issue 9, 2005, Pages 1358-1363

  Petty, S J ^a,b   Paton, L M ^a,b   O'Brien, T J ^a,b   Makovey, J ^c   Erbas, B ^a   Sambrook, P ^c   Berkovic, S F ^a   Wark, John ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; BONE DENSITY; BONE DISEASE; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZYGOTIC TWINS; DRUG EFFECT; ENZYME INDUCTION; EPILEPSY; FEMALE; FEMUR NECK; FOREARM; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MONOZYGOTIC TWINS; PRIORITY JOURNAL; RISK FACTOR; SIBLING;

EID: 27644560546     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000180910.72487.18     Document Type: Article

References (37)

1. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002;31:508-514.
2. Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99:269-275.
3. Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-772.
4. Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005;111:225-228.
5. Souverein PC, Webb DJ, Petri H, Weil J, Van Staa, TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005;46:304-310.
6. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-773.
7. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-342.
8. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-2057.
9. Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002;50:1629-1637.
10. Kruse R. Osteopathies in antiepileptic long-term therapy (preliminary report). Monatsschr Kinderheilkd 1968;116:378-381.
11. Tolman KG, Jubiz W, Sannella JJ, et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 1975;56:45-50.
12. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353.
13. Akin R, Okutan V, Sarici U, Altunbas A, Gokcay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998;19:129-131.
14. Erbayat Altay E, Serdaroglu A, Turner L, Gucuyener K, Hasanoglu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13:933-939.
15. Hahn TJ, Hendin BA, Scharp CR, Boisseau BA, Haddad Jr. JG Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 1975;292:550-554
16. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374.
17. MacInnis RJ, Cassar C, Nowson CA, et al. Determinants of bone density in 30- to 65-year-old women: a co-twin study. J Bone Miner Res 2003;18:1650-1656.
18. Angus RM, Eisman JA. Osteoporosis: the role of calcium intake and supplementation. Med J Aust 1988;148:630-633.
19. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994;330:387-392.
20. Cameron M, Nowson, C, MacInnis, R. et al. A co-twin controlled study of the effect of calcium supplementation on bone density during adolescence. Osteoporos Int 2000;11( suppl 4):S19-S20.
21. Alexander J, Paton L, Margerison C, et al. Pregnancy and lactation have no long-term effect on bone mineral density in a healthy population: a twin study. In: Nutritional aspects of osteoporosis, 2001:303-312.
22. Margerison C, Paton LM, Nowson CA, Ferdous HS, Kaymakci B, Wark JD. Hormone replacement therapy and bone mineral density: a co-twin approach. Menopause 2002;9:436-442.
23. Paton LM, Alexander JL, Nowson CA, et al. Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study. Am J Clin Nutr 2003;77:707-714.
24. Wark JD. Influence of nutrition on bone health: the twin model approach. In: New S, Bonjour JP, eds. Nutritional aspects of bone health. Cambridge: Cambridge University Press, 2003.
25. Paton LBT, Nowson C, Cameron M, et al. A co-twin calcium intervention trial in premenarcheal girls: cortical bone effects by hip structural analysis. Proceedings of 5th International Symposium on Nutritional Aspects of Osteoporosis 2003 (in press).
26. Christian JC, Kang KW. Efficiency of human monozygotic twins in studies of blood lipids. Metabolism 1972;21:691-699.
27. Young D, Hopper JL, Nowson CA, et al. Determinants of bone mass in 10- to 26-year-old females: a twin study. J Bone Miner Res 1995;10:558-567.
28. Flicker L, Hopper JL, Rodgers L, Kaymakci B, Green RM, Wark JD. Bone density determinants in elderly women: a twin study. J Bone Miner Res 1995;10:1607-1613.
29. Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003;44( suppl 4):11-20.
30. Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999;38:93-98.
31. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
32. Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43.
33. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50:93-97.
34. Pack AM, Olarte LS, Morrell MJ, Flaster E, Resor SR, Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003;4:169-174.
35. Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct 25-hydroxyvitamin D levels, calcium and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991;286:113-122.
36. Wark JD, Larkins RG, Perry-Keene D, Peter CT, Ross DL, Sloman JG. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxy-vitamin D. Clin Endocrinol (Oxf) 1979;11:267-274.
37. Caspary WF. Inhibition of intestinal calcium transport by diphenylhydantoin in rat duodenum. Naunyn Schmiedebergs Arch Pharmacol 1972;274:146-153.